HCM experts in the U.K. have found that
extreme left ventricular wall thickness does not automatically correlate with an increased risk of sudden death. Thus, results from a recent study published in the American Heart Association’s Circulation: Arrhythmia and Electrophysiology, suggest that extreme hypertrophy NOT be the sole factor justifying the implantation of an implantable defibrillator.
In the April edition of the American Journal of Cardiology, Italian HCM experts published their findings which indicate that an individual patient’s
HCM causing gene does not influence chances of developing atrial fibrillation and shouldn’t influence the management strategies for the condition.
Image by Ocal - http://www.clker.com/clipart-13766.html
Doctors from Cedars-Sinai Hospital Center for HCM and Aortopathies say that certain blood test results –
specifically BNP and Troponin levels – are useful in evaluating HCM patients, particularly with respect to risk stratification and guidance of medical therapy.
We have all suspected it to be the case, but now a published study proves it:
outcomes of septal reductions done in high volume centers are better than those done in low volume centers. In this study, Dr. Luke Kim, et. al. did a quantitative analysis which showed that septal myectomies and septal alcohol ablation procedures which are performed in high volume centers come out better, while patients have fewer complications post procedure.
editorial written by Drs. Steve Ommen and Rick Nishimura of Mayo Clinic’s HCM Center, citing the research of Kim, makes a very strong case that septal reduction procedures should be done ONLY in high volume centers.